94 related articles for article (PubMed ID: 3378222)
1. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients.
Forastiere AA; Belliveau JF; Goren MP; Vogel WC; Posner MR; O'Leary GP
Cancer Res; 1988 Jul; 48(13):3869-74. PubMed ID: 3378222
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.
Kurihara N; Kubota T; Hoshiya Y; Otani Y; Ando N; Kumai K; Kitajima M
J Surg Oncol; 1996 Jun; 62(2):135-8. PubMed ID: 8649040
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetic evaluation of continuous infusion cisplatin].
Hiura M; Takenawa J; Ryoji O; Taki Y; Hyashi T; Kiriyama T
Hinyokika Kiyo; 1989 Jun; 35(6):955-61. PubMed ID: 2801396
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion.
Belliveau JF; Posner MR; Ferrari L; Crabtree GW; Cummings FJ; Wiemann MC; O'Leary GP; Griffin H; Phaneuf MA; O'Rourke A
Cancer Treat Rep; 1986 Oct; 70(10):1215-7. PubMed ID: 3756943
[TBL] [Abstract][Full Text] [Related]
5. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
6. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion.
Lokich JJ
Cancer Treat Rep; 1980; 64(8-9):905-8. PubMed ID: 6256073
[TBL] [Abstract][Full Text] [Related]
8. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
9. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).
Stewart DJ; Benjamin RS; Zimmerman S; Caprioli RM; Wallace S; Chuang V; Calvo D; Samuels M; Bonura J; Loo TL
Cancer Res; 1983 Feb; 43(2):917-20. PubMed ID: 6681533
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Specenier PM; Ciuleanu T; Latz JE; Musib LC; Darstein CL; Vermorken JB
Cancer Chemother Pharmacol; 2009 Jul; 64(2):233-41. PubMed ID: 19011858
[TBL] [Abstract][Full Text] [Related]
14. [Low-dose CDDP and 5-FU for head and neck cancer patients].
Fujii M; Kanke M; Tomita T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
[TBL] [Abstract][Full Text] [Related]
15. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
[TBL] [Abstract][Full Text] [Related]
17. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
[TBL] [Abstract][Full Text] [Related]
18. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.
Hanauske AR; Schilling T; Heinrich B; Kau R; Herzog M; Quasthoff S; Bochtler H; Diergarten K; Rastetter J
Semin Oncol; 1995 Dec; 22(6 Suppl 14):35-9. PubMed ID: 8553082
[TBL] [Abstract][Full Text] [Related]
19. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic analysis of platinum in the continuous CDDP-CBDCA treatment; its relation to the changes of blood biochemistry].
Chen JT; Hasumi K
Gan To Kagaku Ryoho; 1995 Apr; 22(5):653-7. PubMed ID: 7717717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
